The FrailSafe project
Marina Kotsani Inserm U1116, CHRU Nancy 3 avril 2019, Brussels www.frailsafe-project.eu
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 690140
The FrailSafe project Marina Kotsani Inserm U1116, CHRU Nancy 3 - - PowerPoint PPT Presentation
The FrailSafe project Marina Kotsani Inserm U1116, CHRU Nancy 3 avril 2019, Brussels This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 690140
Marina Kotsani Inserm U1116, CHRU Nancy 3 avril 2019, Brussels www.frailsafe-project.eu
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 690140
www.frailsafe-project.eu
FrailSafe Evaluation per group (A, B, C, D)
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24 M25 M26 M27 M28 M29 M30 M31 M32 M33 M34 M35 M36 Clinical Evaluation n
Group D CONTROL
Clinical Evaluation n M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24 M25 M26 M27 M28 M29 M30 M31 M32 M33 M34 M35 M36 FrailSafe System Clinical Evaluation n Clinical Evaluation n Clinical Evaluation n
Group B PRINCIPAL n=40
FrailSafe System FrailSafe System FrailSafe System FrailSafe System FrailSafe System FrailSafe System Clinical Evaluation n M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24 M25 M26 M27 M28 M29 M30 M31 M32 M33 M34 M35 M36 M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24 M25 M26 M27 M28 M29 M30 M31 M32 M33 M34 M35 M36 Clinical Evaluation n
Group C EVALUATION N=20 EVALUATION n=5
Clinical Evaluation n FrailSafe System FrailSafe System FrailSafe System Clinical Evaluation n Clinical Evaluation n FrailSafe System 60 days M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24 M25 M26 M27 M28 M29 M30 M31 M32 M33 M34 M35 M36 FrailSafe System FrailSafe System Clinical Evaluation n Clinical Evaluation n Clinical Evaluation n
Group A START UP n=80
Clinical study’s rough architecture and main clinical objectives.
www.frailsafe-project.eu
www.frailsafe-project.eu
Frailty is… Very prevalent Multidimentional Dynamically evolutive Difficult to define Difficult to measure Difficult to predict Complex to manage
www.frailsafe-project.eu Monitoring under ecological conditions Multiple metrics in real time Simultaneous multidomain assessment Objectivity in data collection Quick and informative frailty evaluation Hard outcomes’ prediction Addressing accessibility to health care issues Interaction of various actors Opportunity for preventive strategies Addressing risks related to isolation Data traceability for retrospective use
www.frailsafe-project.eu
www.frailsafe-project.eu
www.frailsafe-project.eu
Contact details: m.kotsani@chru-nancy.fr a.benetos@chru-nancy.fr www.frailsafe-project.eu
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 690140